Chronic kidney disease increases the risk of cardiovascular events associated with type 2 diabetes. A clinical trial sought to discover if finerenone would help patients with both of these conditions.
Investigators found a 27% decreased risk of kidney adverse events in a study of patients with normal kidney function or mild-to-moderate chronic kidney disease.
Systematic reviews on this topic have largely been focused on patients receiving dialysis.
This limitation of the kidney failure risk equation may affect advanced care planning for the oldest patients with advanced CKD.
Differences in medication prescription and diagnostic testing are unlikely to fully explain racial disparities in CKD progression and kidney failure, according to investigators.
Researchers evaluated the safety and efficacy of transradial vs transfemoral access in patients with CKD undergoing PCI.
Case finding is more effective than population-based screening at identifying individuals with chronic kidney disease.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection and may lower the risk for hyperkalemia.
A consensus statement from the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) included key areas for research to address challenges in the management of gout in patients with chronic kidney disease.
The current guideline-recommended creatinine-based eGFR equation incorporates a race coefficient that may overestimate eGFR in Black adults and contribute to discordant care.
